Tyra Biosciences, Inc. $TYRA Shares Acquired by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP boosted its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 149.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 198,585 shares of the company’s stock after buying an additional 119,025 shares during the period. Tyra Biosciences accounts for approximately 2.4% of Seven Fleet Capital Management LP’s holdings, making the stock its 9th biggest holding. Seven Fleet Capital Management LP’s holdings in Tyra Biosciences were worth $7,606,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hilton Head Capital Partners LLC acquired a new stake in Tyra Biosciences during the first quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Tyra Biosciences in the 4th quarter worth approximately $51,000. Chung Wu Investment Group LLC acquired a new position in shares of Tyra Biosciences in the 4th quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after acquiring an additional 534 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences in the 1st quarter valued at approximately $276,000. 84.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TYRA. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. Bank of America boosted their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Wolfe Research started coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They set a “peer perform” rating for the company. Guggenheim began coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They issued a “buy” rating and a $50.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and an average price target of $47.00.

Tyra Biosciences Trading Down 3.6%

Shares of NASDAQ TYRA opened at $31.88 on Friday. Tyra Biosciences, Inc. has a 12-month low of $9.96 and a 12-month high of $40.65. The company has a market cap of $1.90 billion, a PE ratio of -14.62 and a beta of 0.76. The stock has a 50 day simple moving average of $30.48 and a 200-day simple moving average of $32.66.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Sell-side analysts forecast that Tyra Biosciences, Inc. will post -2.68 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.